

1. Record Nr.	UNINA9910253946903321
Titolo	Resistance to Targeted Therapies in Breast Cancer // edited by Jenifer R. Properi
Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017
ISBN	3-319-70142-8
Edizione	[1st ed. 2017.]
Descrizione fisica	1 online resource (XV, 184 p. 12 illus. in color.)
Collana	Resistance to Targeted Anti-Cancer Therapeutics, , 2196-5501 ; ; 16
Disciplina	616.99449061
Soggetti	Cancer - Research Cancer Research
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references at the end of each chapters and index.
Nota di contenuto	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
Sommario/riassunto	We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. .